CUREXA HEALTH products and prices in Pakistan
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer - Highnoon subsidiary · Lahore · Pakistan
Lahore-based pharmaceutical manufacturer and wholly owned Highnoon subsidiary specializing in cephalosporin antibiotics and primary and acute-care therapies.
CUREXA HEALTH products in Pakistan
CUREXA HEALTH (PVT.) LIMITED has 23 medicine presentations registered in Pakistan under 6 brands, covering 6 generic medicines. Most of its products are in Anti-infectives. Its brands with the most registered strengths and packs are CEFIA (Cefixime), CEFTRO (Ceftriaxone), CLAFORT (Cefotaxime) and FORTEZ (Ceftazidime). 23 products have an official DRAP price on MedInfoBase. See all 6 brands A to Z
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Private pharmaceutical manufacturer - Highnoon subsidiary
- Address
- Plot No. 517, Sundar Industrial Estate, Lahore, Pakistan
- Website
- curexa.com.pk ↗
- Phone
- +92 42 35298681-4
- info@curexa.com.pk
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where CUREXA HEALTH (PVT.) LIMITED is priced against the market
21 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| CEFIA | Cefixime | 100 mg/5 mL | Suspension | 60ml | 082752 | PKR 533.58 | PKR 8.89/mL | 🔒 Pharma Pro |
| CEFIA | Cefixime | 100 mg/5 mL | Suspension | 30ml | 082752 | PKR 330.39 | PKR 11.01/mL | 🔒 Pharma Pro |
| CEFIA | Cefixime | 400 mg | Capsule | 5's | 082753 | PKR 592.03 | PKR 118.41/capsule | 🔒 Pharma Pro |
| CEFIA | Cefixime | 200 mg/5 mL | Suspension | 30ml | 089439 | PKR 404.33 | PKR 13.48/mL | 🔒 Pharma Pro |
| CEFIA | Cefixime | 200 mg | Capsule | 5's | 095859 | PKR 313.11 | PKR 62.62/capsule | 🔒 Pharma Pro |
| CEFIA | Cefixime | 200 mg | Capsule | 10's | 095859 | PKR 577.41 | PKR 57.74/capsule | 🔒 Pharma Pro |
| Ceflaro 600mg Injection IVRegistry verified | Ceftaroline Fosamil monoacetate monohydrate eq. to ceftaroline fosamil (with L-Arginine) | — | — | — | 014240-EXOfficial source ↗ | No indexed price | — | — |
| Ceftavi 2.5g Injection IVRegistry verified | Ceftazidime Pentahydrate/Sodium carbonate eq. to Ceftazidime 2g & Sterile Avibactam Sodium eq. to Avibactam 0.5g | — | — | — | 012786-EXOfficial source ↗ | No indexed price | — | — |
| Ceftavi 2.5gm Injection IVRegistry verified | Avibactam sodium eq. to Avibactam, Ceftazidime pentahydrate eq. to Ceftazidime | — | — | — | 135406Official source ↗ | No indexed price | — | — |
| CEFTRO | Ceftriaxone | 250 mg | IV injection | 1's Vial | 082737 | PKR 201.47 | PKR 201.47/vial/unit | 🔒 Pharma Pro |
| CEFTRO | Ceftriaxone | 500 mg | IV injection | 1's Vial | 082738 | PKR 339.09 | PKR 339.09/vial/unit | 🔒 Pharma Pro |
| CEFTRO | Ceftriaxone | 500 mg | IM injection | 1's Vial | 082739 | PKR 339.09 | PKR 339.09/vial/unit | 🔒 Pharma Pro |
| CEFTRO | Ceftriaxone | 1 g | IV injection | 1's Vial | 082740 | PKR 640.29 | PKR 640.29/vial/unit | 🔒 Pharma Pro |
| CEFTRO | Ceftriaxone | 250 mg | IM injection | 1's Vial | 082741 | PKR 201.47 | PKR 201.47/vial/unit | 🔒 Pharma Pro |
| CEFTRO | Ceftriaxone | 2 g | IV injection | 1's Vial | 082742 | PKR 897.61 | PKR 897.61/vial/unit | 🔒 Pharma Pro |
| CLAFORT | Cefotaxime | 250 mg | IV/IM injection | 1's Vial | 082743 | PKR 110.89 | PKR 110.89/vial/unit | 🔒 Pharma Pro |
| CLAFORT | Cefotaxime | 500 mg | IV/IM injection | 1's Vial | 082744 | PKR 167.12 | PKR 167.12/vial/unit | 🔒 Pharma Pro |
| CLAFORT | Cefotaxime | 1 g | IV/IM injection | 1's Vial | 082745 | PKR 300.57 | PKR 300.57/vial/unit | 🔒 Pharma Pro |
| CLAFORT | Cefotaxime | 2 g | IV/IM injection | 1's Vial | 082746 | PKR 464.76 | PKR 464.76/vial/unit | No comparator |
| Curexacef | Cephalexin | 500 mg | Capsule | 12's | 094041 | PKR 321.15 | PKR 26.76/capsule | 🔒 Pharma Pro |
| FORTEZ | Ceftazidime | 1 g | IV/IM injection | 1's Vial | 082749 | PKR 479.57 | PKR 479.57/vial/unit | 🔒 Pharma Pro |
| FORTEZ | Ceftazidime | 500 mg | IV/IM injection | 1's Vial | 082750 | PKR 255.31 | PKR 255.31/vial/unit | 🔒 Pharma Pro |
| FORTEZ | Ceftazidime | 250 mg | Injection | 1's Vial | 082751 | PKR 167.86 | PKR 167.86/vial/unit | 🔒 Pharma Pro |
| Fortez | Ceftazidime | 2 g | IV injection | 1's Vial | 113218 | PKR 604.68 | PKR 604.68/vial/unit | No comparator |
| KEFZY | Cefuroxime | 1.5 g | Injection | 1's Vial | 082747 | PKR 359.06 | PKR 359.06/vial/unit | 🔒 Pharma Pro |
| KEFZY | Cefuroxime | 750 mg | Injection | 1's Vial | 082748 | PKR 199.47 | PKR 199.47/vial/unit | 🔒 Pharma Pro |
| Maxum Injection 1g IM/IVRegistry verified | Cefepime hydrochloride eq to cefepime (with L-arginine) | — | — | — | 090509Official source ↗ | No indexed price | — | — |
| Maxum Injection 2g IM/IVRegistry verified | Cefepime (as hydrochloride) (with L-arginine) | — | — | — | 090510Official source ↗ | No indexed price | — | — |
| Maxum Injection 500mg IM/IVRegistry verified | Cefepime hydrochloride eq to cefepime (with L-arginine) | — | — | — | 090508Official source ↗ | No indexed price | — | — |
| Merzel 1gm Injection IVRegistry verified | Meropenem (as Trihydrate) (Blended with sterile sodium carbonate) | — | — | — | 131234Official source ↗ | No indexed price | — | — |
| Merzel 500mg Injection IVRegistry verified | Meropenem (as Trihydrate) (Blended with sterile sodium carbonate) | — | — | — | 131233Official source ↗ | No indexed price | — | — |
| Xorbact Injection 1g IM/IVRegistry verified | Cefoperazone sodium eq to Cefoperazone, Sulbactum as sodium | — | — | — | 082735Official source ↗ | No indexed price | — | — |
| Xorbact Injection 2g IM/IVRegistry verified | Cefoperazone sodium eq to Cefoperazone, Sulbactum as sodium | — | — | — | 082736Official source ↗ | No indexed price | — | — |
| Xorbact Injection 500mg IM/IVRegistry verified | Cefoperazone sodium eq to Cefoperazone, Sulbactum as sodium | — | — | — | 082734Official source ↗ | No indexed price | — | — |
All 6 CUREXA HEALTH brands in Pakistan
- CEFIA Cefixime · 100 mg/5 mL suspension, 200 mg capsule, 200 mg/5 mL suspension
- CEFTRO Ceftriaxone · 1 g injection, 2 g injection, 250 mg injection
- CLAFORT Cefotaxime · 1 g injection, 2 g injection, 250 mg injection
- Curexacef Cephalexin · 500 mg capsule
- FORTEZ Ceftazidime · 1 g injection, 2 g injection, 250 mg injection
- KEFZY Cefuroxime · 1.5 g injection, 750 mg injection
CUREXA HEALTH: common questions
How many products does CUREXA HEALTH have in Pakistan?
CUREXA HEALTH (PVT.) LIMITED has 23 registered medicine presentations in Pakistan, sold under 6 brands and covering 6 generic medicines.
What are the main brands of CUREXA HEALTH?
By number of registered strengths and packs, its largest brands are CEFIA (Cefixime), CEFTRO (Ceftriaxone), CLAFORT (Cefotaxime), FORTEZ (Ceftazidime) and KEFZY (Cefuroxime). This is not a sales ranking.
Which therapy areas does CUREXA HEALTH cover?
The most products are in Anti-infectives (23).
Where can I see CUREXA HEALTH medicine prices?
Open any brand in the list above for its official DRAP price, pack sizes, price history and other brands of the same medicine.
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.